DECR2

Across TCGA pan-cancer cohorts, DECR2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DECR2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DECR2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DECR2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where DECR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.381	0.951	.006	12	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.911	.042	4	view →
LUAD	DFS	Quartile	All	0.778	0.994	.027	3	view →
CCRCC	OS	Median	III,IV	1.000	0.842	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DECR2–PDAC (OS)

Open the PDAC breakdown →